Key result
TAVR is linked to ~46% lower in-hospital mortality compared to SAVR.
Why the study?
Predictors and trends of in-hospital mortality following SAVR and TAVR between 2011 and 2019, as well as the association between peripheral artery disease and mortality after TAVR, were not fully described.
Does TAVR reduce postoperative in-hospital mortality compared to SAVR in patients with aortic stenosis?
Cohort (n=129,305)
Yes
Does TAVR reduce postoperative in-hospital mortality compared to SAVR in patients with aortic stenosis?
Effect estimate: OR 0.54
p-value: p=<0.001
TAVR-related in-hospital mortality has decreased over time to below SAVR levels, and comorbid peripheral artery disease does not significantly increase in-hospital mortality risk after TAVR.
TAVR appears safe even in patients with comorbid peripheral artery disease, but as observational data, this.
INTRODUCTION: Since 2011, transcatheter aortic valve replacement (TAVR) is an alternative to surgical valve replacement (SAVR). The objective was to describe predictors and trends of in-hospital mortality risk following SAVR and TAVR between 2011 and 2019. We also describe the underinvestigated association between peripheral artery disease (PAD) and mortality risk after TAVR. METHODS: Using a retrospective cohort from the National Inpatient Sample database, we identified operations with TAVR and SAVR as primary or secondary procedures and indication of aortic stenosis. The primary outcome was postoperative in-hospital morality. Sample-weighted logistic regression was used to examine the association between operation type and in-hospital mortality with interaction terms to describe change in mortality over time. RESULTS: Between 2011 and 2019, 129,305 patients were included: 82,583 (63.9%) SAVRs and 46,722 (36.1%) TAVRs. Influential predictors of mortality included age (odds ratio [OR] = 1.03 and p < 0.001), elective case status (OR = 0.55 and p < 0.001), and operation type (TAVR OR = 0.54 and p < 0.001). Procedure-related mortality risk changed significantly over time (p < 0.001). Initially (2011-2014), TAVR-associated mortality risk was higher than SAVR but this risk decreased substantially after 2014. PAD was not a significant predictor of in-hospital mortality among patients undergoing TAVR (OR = 0.98 and p = 0.91). CONCLUSION: TAVR-related mortality risk was initially higher than SAVR-related mortality, but this risk substantially decreased to below SAVR levels in the later period of study. In this cohort study, PAD was not a significant predictor of in-hospital mortality after TAVR.
No takes yet. Share an insight, caveat, or question.
Faridmoayer et al. (2025) conducted a cohort in aortic stenosis (n=129,305). TAVR vs. SAVR was evaluated on postoperative in-hospital mortality (OR 0.54, p=<0.001). TAVR was associated with lower overall in-hospital mortality than SAVR (OR 0.54, p<0.001), and peripheral artery disease was not a significant predictor of mortality after TAVR (OR 0.98, p=0.91).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: